NCT00378521

Brief Summary

The Purpose of this study is to determine the response to two different strengths of a topical gel containing nitroglycerin in patients with Raynaud's disease.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Jul 2006

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2006

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

September 18, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 20, 2006

Completed
Last Updated

May 30, 2007

Status Verified

May 1, 2007

First QC Date

September 18, 2006

Last Update Submit

May 29, 2007

Conditions

Keywords

Raynaud'sNitroglycerintopical gelcold handspainful handsscleroderma

Outcome Measures

Primary Outcomes (1)

  • Measure the time required for blood flow to return to baseline after cold exposure

Secondary Outcomes (2)

  • Measure the time required for skin temperature to return to baseline after cold exposure

  • Prevention or reduction of symptoms following cold exposure.

Interventions

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Outpatients, 18 to 75 years
  • Clinical Diagnosis of Raynaud's, or observed event by study physician, or symptoms with reduced blood flow as meausred using laser doppler equipment
  • Agree to have test gels applied to finger
  • Discontinue current vasodialator therapeis for Raynaud's treatment
  • Four weeks from last clinical trial participation
  • Agree not to use any other investigational medications or therapies to treat Raynaud's and its symptoms while participating in this study including other dosages or forms of nitroglycerin, isosorbide dinitrate, fenoldopam mesylate, milrinone lactate, nifedipine, diltiazem, felodipine, nimodipine, nisoldipine, and verapamil
  • Negative pregnancy test for women prior to study start and agree to use effective contraception throughout
  • Must be able to give written informed consent and comply with all study requirements

You may not qualify if:

  • Concurrent use of any nitrate medication or medications known to interact with Nitroglycerin such as sildenafil, and other treatments for erectile dysfunction
  • Patients who have a known allergy to Nitroglycerin or common topical gel ingredients
  • Patients with a history of migraine, cluster or vascular headaches, or those who suffer from chronic pain
  • Patients with a history of an unstable medical problem or any current condition that would interfere in participation in the study
  • Patients unable to complete pain assessment instructions
  • Patients who in the last three months have had a myocardial infarction, uncontrolled congestive heart failure, unstable angina, uncontrolled hypotension or uncontrolled hypertension
  • Patients who have participated in another investigational drug study within four weeks of the first study treatment
  • Patients with out of range laboratory screening values
  • Patients who have had major abdominal, thoracic or vascular surgery within six months of the first study treatment
  • Patients with open lesions or skin conditions where gel is to be applied
  • Pregnant or nursing women
  • Women who will not agree to comply with contraceptive requirements
  • Patients with a history of poor compliance, poor cooperation or unreliability

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rainier Clinical Research

Renton, Washington, 98055, United States

Location

MeSH Terms

Conditions

Raynaud DiseaseScleroderma, Diffuse

Condition Hierarchy (Ancestors)

Livedoid VasculopathyThrombosisEmbolism and ThrombosisVascular DiseasesCardiovascular DiseasesPeripheral Vascular DiseasesSkin Diseases, VascularSkin DiseasesSkin and Connective Tissue DiseasesScleroderma, SystemicConnective Tissue Diseases

Study Officials

  • Leslie Klaff, MD

    Rainier Clinical Research

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

September 18, 2006

First Posted

September 20, 2006

Study Start

July 1, 2006

Study Completion

July 1, 2006

Last Updated

May 30, 2007

Record last verified: 2007-05

Locations